axicabtagene ciloleucel
Gilead,Daiichi Sankyo
['axi-cel', 'love it', 'lymsm']
i would love it if speakers at #ash22 #lymsm would expand upon their criteria for a treatment being 'well-tolerated'. for 2l axi-cel in asct-ineligible alycante study: 8/40 grade 3+ icans, and 30% of all patients required icu admission... just curious what their priors were.
Oncology fellow @SitemanCenter @WUHemeOncFellow @WUSTLmed | lymphoma/leukemia researcher @LabFehniger | all views 100% my own